CBPO Stock News 40.42 05/13/2014 19:36:16 China Biologic Products

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
China Biologic Products (CBPO) 40.42 $CBPO

China Biologic Reports Financial Results for the First Quarter of 2014
PR Newswire - Tue May 06, 4:00PM CDT
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company" , a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the first quarter of 2014.

China Biologic Products to Report First Quarter 2014 Financial Results
PR Newswire - Tue Apr 29, 7:30AM CDT
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company" , a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release first quarter 2014 financial results on Tuesday, May 6, 2014 after the market closes.

Global Critical Care Market 2013-2019
M2 - Fri Apr 11, 2:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/prjqh7/critical_care) has announced the addition of the "Critical Care Market to 2019 - Growth from Factor Concentrates New Indications and Increasing Demand for Albumin in Asia-Pacific" report to their offering. The overall critical care therapeutics market was worth $2.3 billion in 2012, having grown in size at a CAGR of 11% from $1.2 billion in 2006. The market is expected to grow at a CAGR of 5% to reach $3.2 billion in 2019. The double-digit market growth registered between 2006 and 2012 can be attributed primarily to the increased demand for and cost of albumin, as well as the approval and launch of new products. The report analyzes the markets for factor XIII concentrates, fibrinogen concentrates, albumins, antithrombins and prothrombin complex concentrates in the US, the top five countries of Europe (the UK, Germany, France, Italy and Spain), and Japan. The report does also provide an overview on Asia-Pacific countries, including China, India and Australia. The report provides an overview of major marketed products in critical care market along with treatment usage patterns, average annual cost of therapy and market forecast to 2019 for key geographical markets, as well as for leading therapeutic segments. The report also provides information on the Research and Development (R&D) product pipeline and explores the competitive landscape, including the provision of profiles for major players in the critical care market. Finally, the report includes analysis of Mergers and Acquisitions (M&A) activity in the critical care market. The growth of the overall critical care market during the forecast period is expected to be largely due to an increasing preference in the market for factor concentrates such as Riastap, Corifact, rFXIII (which has been launched in the EU and is expected to be launched in the US later this year), the expanded indication for Antithrombin (AT) III and factor concentrates, and rising demand for albumin from countries in the Asia-Pacific region. Stagnant innovations, a low prevalence rate and the consequent limited availability of patients are some of the factors impeding the growth of the critical care market. Key Topics Covered: - Tables & Figures - Introduction - Critical Care Market to 2019 - Global Overview - Critical Care Market to 2019 - Geographical Landscape - Critical Care Market to 2019 - Albumin Market - Critical Care Market to 2019 - Antithrombin Concentrate Market - Critical Care Market to 2019 - Fibrinogen Concentrate Market - Critical Care Market to 2019 - Prothrombin Complex Concentrate Market - Critical Care Market to 2019 - Factor XIII Concentrate Market - Critical Care Market to 2019 - Research and Development Product Pipeline - Critical Care Market to 2019 - Competitive Landscape - Critical Care Market to 2019 - Strategic Consolidation - Critical Care Market to 2019 - Appendix Companies Mentioned - Baxter International Incorporated - Bio Products Laboratory Limited - Biotest - China Biologic Products, Incorporated - CSL Limited - Grifols, SA - Hualan Biological Engineering, Incorporated - Kedrion SpA - aboratoire Fran?ais de Fractionnement et de Biotechnologies - Octapharma AG - Sanquin Blood Supply Foundation - Shanghai RAAS Blood Products Company, Limited For more information visit http://www.researchandmarkets.com/research/pr...tical_care

China Biologic Products, Inc. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of China Biologic Products, Inc.
Business Wire - Tue Apr 08, 12:48PM CDT
Levi & Korsinsky, LLP is investigating China Biologic Products, Inc. (NasdaqGS: CBPO) in connection with possible claims of breaches of fiduciary duty.

China Biologic Announces Favorable Resolution to Title Dispute Involving Company Shares
PR Newswire - Wed Apr 02, 7:30AM CDT
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company" , a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company has learned that the pending claim in the High Court of Hong Kong (the "Court" against Ms. Siu Ling Chan ("Ms. Chan" , an individual shareholder of the Company, and her spouse, Mr. Tung Lam, had been withdrawn with Court approval. The claim was originally filed by a group of individuals against the title of certain shares of the Company's common stock held by Ms. Chan and Ms. Lin Ling Li ("Ms. Li" , a formal individual shareholder of the Company.

China Biologic Announces Receiving GMP Certification at its Guizhou Taibang Facility
PR Newswire - Wed Mar 19, 7:30AM CDT
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company" , a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company has received the Good Manufacturing Practice ("GMP" certification from China Food and Drug Administration ("CFDA" in respect of its plasma production facility at its Guizhou subsidiary.

China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2013
PR Newswire - Wed Mar 12, 4:00PM CDT
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company" , a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year 2013.

China Biologic Products to Report Fourth Quarter and Fiscal Year 2013 Financial Results
PR Newswire - Tue Mar 04, 5:00AM CST
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company" , a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release fourth quarter and fiscal year 2013 financial results on Wednesday, March 12, 2014 after the market closes.

China Biologic Products reports repurchase of 2.5m shares of common stock
M2 - Mon Mar 03, 6:28AM CST
Biopharmaceutical company China Biologic Products (NASDAQ:CBPO) said on Monday that it has repurchased 2.5m common shares at USD28.00 per share for an aggregate of USD70m .

China Biologic Completes Stock Repurchase Transaction
PR Newswire - Mon Mar 03, 5:00AM CST
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company" , a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company has completed its repurchase of 2.5 million shares of common stock for a total consideration of $70 million. This transaction was originally announced in the Company's 8-K SEC filing on January 28, 2014.

Concise Analysis of the International Intravenous Immunoglobulin (IVIg) Market
M2 - Tue Feb 25, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/m8bpfg/intravenous) has announced the addition of the "Concise Analysis of the International Intravenous Immunoglobulin (IVIg) Market" report to their offering. This report analyzes the worldwide markets for Intravenous Immunoglobulin (IVIg) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 27 companies including many key and niche players such as: - Baxter International Inc. - Beijing Tiantan Biological Products Co. Ltd. - Bharat Serums and Vaccines Ltd. - Biotest AG - China Biologic Products Inc. - Guizhou Taibang Biological Products Co. Ltd. - CSL Limited - CSL Behring - Grifols S.A - Huanlan Biological Engineering Inc. - Kedrion S.p.A. - LFB Group - Octapharma AG - OMRIX Biopharmaceuticals Ltd. - Shanghai RAAS Blood Products Co. Ltd. - Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Plasma Proteins - An Overview 3. Immunoglobulins - An Overview 4. Therapy Overview 5. Regulatory Approvals 6. Product Innovations/Introductions 7. Recent Industry Activity 8. Focus On Select Players 9. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 27 (including Divisions/Subsidiaries - 34) - The United States (9) - Canada (2) - Japan (2) - Europe (9) - France (2) - Germany (1) - The United Kingdom (1) - Italy (1) - Spain (1) - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (11) - Middle-East (1) For more information visit http://www.researchandmarkets.com/research/m8...ntravenous

3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Feb 22, 7:25AM CST
Champions weren't just basking in glory at the Sochi Winter Olympic games this week. The world of health care produced quite a few stocks deserving gold medals in their own way.  Breaking news about a big acquisition propelled one of our humongous...

3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 20, 3:25PM CST
Feel free to log our early-2014 "correction" as a distant memory, because the broad-based S&P 500 is once again within striking distance of another all-time closing high. For skeptics like me, that's an opportunity to see whether companies have...

Nasdaq stocks posting largest percentage increases
AP - Wed Feb 19, 5:13PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:

Global Plasma Market 2012-2016 with Baxter International Inc., CSL Behring LLC, Grifols S.A., and Octapharma AG Dominating
M2 - Tue Feb 04, 9:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/lqj4jb/global_plasma) has announced the addition of the "Global Plasma Market 2012-2016" report to their offering. This report forecasts the Global Plasma market to grow at a CAGR of 10.31 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in the aging population. The Global Plasma market has also been witnessing the trend of increasing market consolidation. However, stringent regulations could pose a challenge to the growth of this market. Key vendors dominating this space CSL Behring LLC, Baxter International Inc., Grifols S.A., and Octapharma AG Other vendors mentioned in the report are Kedrion S.p.A., Biotest AG, Sanguine Corp., Cangene bioPharma Inc., Haemacure Corp., Kamada Inc., Omrix Biopharmaceuticals Inc., Vivostat A/S, Pfizer Inc., AstraZeneca plc, Takeda Pharmaceutical Inc., Novo Nordisk A/S, sanofi S.A., China Biologic Products Inc., Beijing Tiantan Biological Products Co. Ltd., Bharat Serums and Vaccines Ltd., and LFB Group. This report Global Plasma Market 2012-2016 is based on an in-depth analysis covering the Americas, the EMEA region, and the APAC region. The report aims to aid decision makers' understanding of the present and future landscape of the market. Commenting on the report, an analyst from the Healthcare team said: 'Over the years, the Global Plasma market has been witnessing significant consolidation and as a result the positions of the leading players have shifted dramatically over the past decade. This trend is expected to continue during the forecast period as vendors attempt to strengthen or hold their market position. Market consolidation has resulted in stronger competitors that are better able to compete as sole-source vendors to end-users. For instance, Australia-based CSL Behring has become one of the world's leading fractionators through a series of acquisitions including its 2000 buyout of ZLB Behring and 2004 purchase of Aventis Behring. Grifols acquisition of Talecris Biotherapeutics has further consolidated the industry.' For more information visit http://www.researchandmarkets.com/research/lq...bal_plasma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2013 Research Report
M2 - Thu Jan 23, 8:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/6c4qdd/fibrinogen) has announced the addition of the "Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2013" report to their offering. 'Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency). Scope - A snapshot of the global therapeutic scenario for Fibrinogen Deficiency (Factor I Deficiency). - A review of the Fibrinogen Deficiency (Factor I Deficiency) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Fibrinogen Deficiency (Factor I Deficiency) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Fibrinogen Deficiency (Factor I Deficiency). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Fibrinogen Deficiency (Factor I Deficiency) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Biotest AG Pharming Group N.V. Octapharma AG LFB S.A. China Biologic Products, Inc. For more information visit http://www.researchandmarkets.com/research/6c4qdd/fibrinogen About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

China Blood Product Market Analysis & 2015 Forecasts in New Research Report at ChinaMarketResearchReports.com
PRWeb - Mon Dec 30, 8:32PM CST
Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due to the implementation of favorable policies, widening gap between supply and demand, rising product prices and other factors, more than 150 plasma stations in China produced about 3,600 tons of plasma in 2012, up 14.2% year on year. From 2012 to mid-2013, new plasma stations of some Chinese enterprises have started plasma collection or obtained plasma collection permits, such as Yuechi plasma station of Jiangxi Boya Bio-Pharmaceutical, Changyuan plasma station of Hualan Bio, and Caoxian plasma station of China Biologic Products. It's expected that China's plasma supply tension will be further eased after 2013.

Is This the Most Undervalued Biotech of 2013?
Keith Speights, The Motley Fool - Motley Fool - Sun Dec 15, 4:15PM CST
If you were looking for a hot sector to buy at the beginning of 2013, biotech was it. The iShares Nasdaq Biotechnology ETF has soared more than 56% this year with only a few weeks to go. With biotech sizzling, you might think it would be hard to...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Adecco Finds AI Value Depends on Better Work Redesign

Updated Category News Views 39

A shiny AI license is not a productivity strategy, and Adecco's latest workforce survey puts some hard numbers behind that irritation. The company surveyed 40,500 workers in 36 countries for its seventh Global Workforce of the Future report, released November 19, 2026. Its central finding is disarmingly sensible: AI produces more when companies rebuild the work around it...

Continue Reading
Lake Ridge Sets $0.68 Dividend as 2026 Payouts Rise

Updated Category News Views 128

A community bank raising its cash return is not fireworks, but it gets my attention faster than another glossy growth slogan. Lake Ridge Bancorp has declared a fourth-quarter 2026 dividend of $0.68 per share, payable December 16 to shareholders of record on November 30. That is a plain, useful announcement from OTCQX:LRBI, and plain is often underrated when you are...

Continue Reading
Chemours Legal Succession Gets a Long Transition Runway

Updated Category News Views 164

A corporate-law handoff rarely sets pulses racing, but this one deserves a proper look. Chemours is replacing its long-serving general counsel while keeping the departing executive in the building for four additional months. That is not flashy, and thank goodness for that. In a global chemicals company, legal leadership touches regulation, compliance, governance,...

Continue Reading
BVM's Brookfield Headquarters Move Tests Growth Ambition

Updated Category News Views 152

A bigger office is rarely the exciting part of a growth story, yet it can reveal whether the machinery underneath is actually running hot. Best Version Media has moved its headquarters from Janacek Court to 15800 W. Bluemound Road, Suite 400, in Brookfield, Wisconsin, citing room for recent hires, future recruitment and closer collaboration across its print and digital...

Continue Reading
Tronox Pushes Back on Creditor Restructuring Chatter Firmly

Updated Category News Views 146

A Creditor Rumor Is Not a Restructuring Plan Two creditor groups hiring law firms can make a stock chart look like it stepped on a rake, but it is not the same thing as a debt workout. That distinction is the whole point of Tronox Holdings' November 18 update. A November 17 Wall Street Journal report said two groups of creditors had retained firms described as...

Continue Reading
V2’s FOAS Bets on Candid Ad Sales Operator Dialogue

Updated Category News Views 14

Ad sales rarely gets fixed by another ballroom panel, and V2 seems to know it. Its new Future of Ad Sales, or FOAS, forum is built around a simpler premise: put senior operators in a small room, keep vendors and conference theatrics out of the way, and let people compare the ugly real-world details of running revenue machines. Announced November 19, 2026, FOAS is an...

Continue Reading
Shenzhen’s APEC Moment Puts Pacific Trade Links in Focus

Updated Category News Views 97

A city that once logged eight stock trades in a day is hosting APEC with a very different kind of ledger in view. Shenzhen Stock Exchange began trial operations on December 1, 1990 with one stock, eight trades and roughly 200,000 yuan in turnover. By the end of September 2026, it had 2,908 listed companies and about 42.43 trillion yuan in combined market value. That is...

Continue Reading
Borr’s Q3 Presentation Puts Jack-Up Investors on Watch

Updated Category News Views 17

Jack-up drilling is a rough business to judge from a calendar invite, but Borr Drilling has put a useful marker in the sand. The company is scheduled to present financial results for the three and nine months ended September 30, 2026, at 09:00 New York time, or 15:00 CET, on Thursday, November 19. For holders of BORR, this is less about ceremonial webcast chatter and more...

Continue Reading
DoorDash Grocery Tools Need a Hard Look Before Checkout

Updated Category News Views 30

A grocery cart built in thirty seconds can still nick your wallet all week. That is the part buried beneath the convenience pitch around DoorDash's grocery tools: planning is useful, but convenience only earns its keep when the final basket, delivery charge, substitutions, and timing actually line up. The 2026 review from Expert Consumers highlights features that are...

Continue Reading
MSD's AI Drug Bet Has Promise, but Plenty to Prove

Updated Category News Views 55

A promising molecule remains a very expensive guess until biology agrees. That is the sober lens for MSD's newly announced research collaboration with Isomorphic Labs: potentially meaningful science, certainly interesting strategic positioning, and absolutely no reason yet to start penciling in product sales. One Oncology Target, Not a Finished Drug On November 19, 2026,...

Continue Reading

Top 5 Most Recently Viewed Articles

Join Us for Engaging Insights at the Boston IT Summit

Updated Category News Views 115

On November 7th, the Boston Cloud Connect Summit brought together industry heavyweights to tackle pressing issues in cybersecurity and artificial intelligence. With tech's rapid evolution, you know this ain't just some run-of-the-mill conference; it’s a showcase of brains tackling real threats. Cybersecurity Insights: Joe Flores at the Helm Joe Flores, Massachusetts...

Continue Reading
Revolutionizing Fitness and Entertainment: HYROX Partners with Legendz

Updated Category News Views 306

HYROX Teams Up with Legendz for Unmatched Experiences HYROX, a leader in the world of fitness racing, has announced an exciting partnership with Legendz Social Sportsbook & Casino, aiming to merge the world of competitive fitness with top-tier entertainment. This collaboration will not only uplift the profile of fitness events but also enhance fan engagement like never...

Continue Reading
DXC Technology Teams with Ferrari for Advanced Automotive HMI

Updated Category News Views 210

DXC Technology Partners with Ferrari for Next-Gen HMI Development DXC Technology (NYSE: DXC) has entered a groundbreaking partnership with Ferrari aimed at transforming the driver experience through advanced Human Machine Interface (HMI) systems in the latest automotive models. This collaboration allows DXC to leverage its extensive expertise in the automotive sector to...

Continue Reading
CEO Aman Narang's Selling Decision Raises Investor Interest

Updated Category News Views 250

Understanding the Recent Insider Sale at Toast A recent SEC filing has brought to light an important transaction involving Aman Narang, the CEO of Toast (NYSE: TOST). On a notable day, Narang sold 1,732 shares of Toast, amounting to a total value exceeding $61,000. This insider action inevitably attracts the attention of seasoned investors and market observers alike....

Continue Reading
Blue Cross and Blue Shield of Montana: Quality Health Coverage For All

Updated Category News Views 259

Blue Cross and Blue Shield of Montana Enhances Health Offerings Blue Cross and Blue Shield of Montana (BCBSMT) is dedicated to providing quality individual and family health insurance plans across Montana as the open enrollment period commences. Experience and Availability of Plans For over 85 years, BCBSMT has been a cherished provider in Montana, actively extending its...

Continue Reading
om Blog Section End -->